By Logan Kastner, Director of Marketing and Development
We have so much to be thankful for and to celebrate this year. In the spirit of Thanksgiving, it makes sense to pause and reflect on our mission, our progress and express our gratitude to our supporters who have helped us come so far.
MRA remains committed to accelerating the pace of scientific discovery by continuing to fund translational research in the field of melanoma. Since 2007, we have fully funded nearly $68 million in research, leveraged an additional $80 million from our partners, bringing the overall funding to more than $148 million to help combat this terrible disease.
Eight years ago, only two approved treatment options were available for patients who were diagnosed with advanced melanoma. Today, we are delighted to now have 11 approved therapies available, and MRA has provided funding to study each one of these therapies This is tremendous progress, and we hear from patients regularly who are alive thanks to these new treatments.
The impact of our funded research doesn’t stop with melanoma.
MRA-funded research has also energized the entire field of oncology. Thanks to the success of immunotherapy, targeted therapies, and combination approaches, MRA has played a fundamental role in charting a new course in cancer treatments for over 30 different varieties of tumor types.
This unprecedented rate of progress would not have happened without the incredibly generous support of our founders, donors, and partners. Unfortunately, our work is far from over. We still have segments of the patient population who are not responding to the current treatment options available. This means we have more work to do and more research to support.
Together, with your support, we can continue our mission to fund vital research bringing us closer than ever before to finding a cure. We are grateful that so many patients will now get to spend the holidays with their loved ones. Thanks to all of you who have helped us get to this point.